Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Open Label, Multicentre Phase Iv Study To Evaluate The Efficacy And Safety Of Magnex (Cefoperazone-Sulbactam) In Comparison With Ceftazidime Plus Amikacin And Metronidazole In The Treatment Of Intra-Abdominal Infections

NCT00360607 is registered in ClinicalTrials.gov with Pfizer as lead sponsor.

NCT NCT00360607
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00360607 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Open Label, Multicentre Phase Iv Study To Evaluate The Efficacy And Safety Of Magnex (Cefoperazone-Sulbactam) In Comparison With Ceftazidime Plus Amikacin And Metronidazole In The Treatment Of Intra-Abdominal Infections
Lead sponsor
Pfizer
Phase
Phase 4
Overall status
Completed
Start date
July 31, 2004
Completion date
April 30, 2005
Enrollment
307 (actual)
Sites
20

Conditions

As the registry lists them; a condition with its own page is linked.

infection